close

QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle. The company was founded in 1981 and is headquartered in Vancouver, Canada.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	7.27
Volume	57663
Volume Avg	118548
52 Week High	8.87
52 Week Low	5.35
PE	N/A
PE (group average)	39
EPS Year	-0.61
EPS change Q/Q	-55.26%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	-10.53%
EPS change Y/Y	-1000%
REV change Q/Q	-11%
REV change Q/Q Yr ago	-35.04%
EPS next Q est	-0.19
EPS next Y est	-1.05
Divident Annual	0.00
Dividend Yield	0%